The NDA submission timeline is the primary catalyst — watch for actual filing in early Q4 2026 and any FDA feedback. Cash runway is tight through late Q4 2026, so a capital raise (equity or partnership) is likely in the coming months. The new biomarker data strengthens the NDA package but does not change the binary approval risk. Consider position sizing accordingly given the pre-revenue stage and historical volatility.
Price Chart
Executive Summary
Clene reported Q2 2026 results with a net loss of $13.4M ($1.08/share), widening from $7.4M ($0.78/share) a year ago, driven largely by non-cash warrant and derivative revaluation charges. Operationally, the R&D and G&A expense reduction narrowed the operating loss to $5.3M from $5.9M. The key catalyst is the planned NDA submission for CNM-Au8 in ALS under the accelerated approval pathway, now expected in early Q4 2026 (slightly delayed from prior Q3 guidance). New biomarker analyses showed survival and functional benefit in patients with NfL decline/stabilization. Cash of $9.7M plus recent debt amendments provide runway through late Q4 2026, but additional financing will likely be needed.
Key Financial Metrics
Key Facts
- NDA submission for CNM-Au8 in ALS under accelerated approval pathway expected early Q4 2026 (slipped from prior Q3 2026 guidance)
- New biomarker analyses show CNM-Au8-treated patients with NfL decline/stabilization lived significantly longer and performed better on functional measures vs controls
- Cash and cash equivalents $9.7M at June 30, 2026, up from $5.2M at Dec 31, 2025; operating runway through late Q4 2026
- Net loss $13.4M in Q2 2026 vs $7.4M in Q2 2025; operating loss improved to $5.3M from $5.9M
- In May 2026, closed $7M registered direct offering and amended $10M + $1.5M convertible debt facilities to extend maturity to Aug 2027 with no principal/interest payments before maturity
Financial Impact
Net loss widened by $6.0M YoY to $13.4M; operating loss narrowed by $0.5M to $5.3M; cash position improved by $4.5M since year-end 2025
Risk Factors
- Cash runway only through late Q4 2026; additional financing needed, likely dilutive
- NDA submission delay or rejection risk; FDA may require additional data
- Pre-revenue stage with no approved products; stock price highly sensitive to pipeline news
- Significant non-cash charges from warrant/derivative revaluation create earnings volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-027837 |
| Document: clnn20260524_8k.htm | 0001437749-26-027837 |
| Document: 0001437749-26-027837-index-headers.html | 0001437749-26-027837 |
| Document: 0001437749-26-027837-index.html | 0001437749-26-027837 |
| Document: 0001437749-26-027837.txt | 0001437749-26-027837 |
| 8-K Data (Synthetic) | 0001437749-26-027837 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $3.73 | awaiting T+20 | — | $3.97 (+6.43%) |
Oct 19, 2026 8d ago | 8-K | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 19, 2026 8d ago | Press Release | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 13, 2026 14d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.97 (+17.11%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.97 (+4.34%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.97 (−2.85%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.97 (−23.06%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.97 (−43.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers